Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer

Jana Heitmann, Paul Geeleher, Zhixiang Zuo, Ralph R. Weichselbaum, Everett E. Vokes, Sebastian Fetscher, Tanguy Lim Seiwert

Research output: Contribution to journalArticle

Abstract

Objectives Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown single agent activity against tumors with deficiencies in the DNA repair mechanism homologous recombination including, but not limited to those harboring BRCA mutations. We hypothesized that, in the context of homologous recombination deficiency (HRD), PARPi could have an effect in head and neck cancer (HNC). Materials and Methods We evaluated TCGA data for evidence of HRD using a copy number data signature established for breast cancer. The comparative potency of three PARPi was evaluated using cell viability assays in a panel of HNC cell lines and response was compared to BRCA-deficient breast cancer cell lines. The change in foci formation of γH2AX and RAD51 was assessed with immunofluorescent staining after exposure to a PARPi. Baseline gene expression was analyzed using microarray data. Results We found a subgroup in the TCGA HNC cohort harboring genomic aberrations consistent with HRD in breast cancer. Rucaparib activity was superior to olaparib and veliparib and showed single agent activity in a subset of HNC cell lines that was comparable to BRCA-deficient breast cancer cell lines. Rucaparib-sensitive and rucaparib-resistant groups showed significant differences in γH2AX and RAD51 foci formation after rucaparib exposure. Expression of genes involved in chromosome structure was strongly associated with rucaparib resistance. Conclusion We demonstrate that PARPi are effective in a subset of HNC cell lines and propose that HRD may be present in HNC in vivo suggesting that these compounds could play a role in the treatment of HNC.

Original languageEnglish (US)
Pages (from-to)825-831
Number of pages7
JournalOral Oncology
Volume50
Issue number9
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Homologous Recombination
Cell Line
Breast Neoplasms
DNA Repair-Deficiency Disorders
Chromosome Structures
Gene Expression
Recombinational DNA Repair
Poly(ADP-ribose) Polymerase Inhibitors
Cell Survival
rucaparib
Staining and Labeling
Mutation
Neoplasms

Keywords

  • DNA repair
  • Head and neck cancer
  • Homologous recombination
  • Poly (ADP-ribose) polymerase
  • Rucaparib

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

Heitmann, J., Geeleher, P., Zuo, Z., Weichselbaum, R. R., Vokes, E. E., Fetscher, S., & Lim Seiwert, T. (2014). Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. Oral Oncology, 50(9), 825-831. https://doi.org/10.1016/j.oraloncology.2014.06.004

Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. / Heitmann, Jana; Geeleher, Paul; Zuo, Zhixiang; Weichselbaum, Ralph R.; Vokes, Everett E.; Fetscher, Sebastian; Lim Seiwert, Tanguy.

In: Oral Oncology, Vol. 50, No. 9, 01.01.2014, p. 825-831.

Research output: Contribution to journalArticle

Heitmann, J, Geeleher, P, Zuo, Z, Weichselbaum, RR, Vokes, EE, Fetscher, S & Lim Seiwert, T 2014, 'Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer', Oral Oncology, vol. 50, no. 9, pp. 825-831. https://doi.org/10.1016/j.oraloncology.2014.06.004
Heitmann J, Geeleher P, Zuo Z, Weichselbaum RR, Vokes EE, Fetscher S et al. Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. Oral Oncology. 2014 Jan 1;50(9):825-831. https://doi.org/10.1016/j.oraloncology.2014.06.004
Heitmann, Jana ; Geeleher, Paul ; Zuo, Zhixiang ; Weichselbaum, Ralph R. ; Vokes, Everett E. ; Fetscher, Sebastian ; Lim Seiwert, Tanguy. / Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. In: Oral Oncology. 2014 ; Vol. 50, No. 9. pp. 825-831.
@article{8e02e70c66aa45a59290433f325649ab,
title = "Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer",
abstract = "Objectives Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown single agent activity against tumors with deficiencies in the DNA repair mechanism homologous recombination including, but not limited to those harboring BRCA mutations. We hypothesized that, in the context of homologous recombination deficiency (HRD), PARPi could have an effect in head and neck cancer (HNC). Materials and Methods We evaluated TCGA data for evidence of HRD using a copy number data signature established for breast cancer. The comparative potency of three PARPi was evaluated using cell viability assays in a panel of HNC cell lines and response was compared to BRCA-deficient breast cancer cell lines. The change in foci formation of γH2AX and RAD51 was assessed with immunofluorescent staining after exposure to a PARPi. Baseline gene expression was analyzed using microarray data. Results We found a subgroup in the TCGA HNC cohort harboring genomic aberrations consistent with HRD in breast cancer. Rucaparib activity was superior to olaparib and veliparib and showed single agent activity in a subset of HNC cell lines that was comparable to BRCA-deficient breast cancer cell lines. Rucaparib-sensitive and rucaparib-resistant groups showed significant differences in γH2AX and RAD51 foci formation after rucaparib exposure. Expression of genes involved in chromosome structure was strongly associated with rucaparib resistance. Conclusion We demonstrate that PARPi are effective in a subset of HNC cell lines and propose that HRD may be present in HNC in vivo suggesting that these compounds could play a role in the treatment of HNC.",
keywords = "DNA repair, Head and neck cancer, Homologous recombination, Poly (ADP-ribose) polymerase, Rucaparib",
author = "Jana Heitmann and Paul Geeleher and Zhixiang Zuo and Weichselbaum, {Ralph R.} and Vokes, {Everett E.} and Sebastian Fetscher and {Lim Seiwert}, Tanguy",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.oraloncology.2014.06.004",
language = "English (US)",
volume = "50",
pages = "825--831",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer

AU - Heitmann, Jana

AU - Geeleher, Paul

AU - Zuo, Zhixiang

AU - Weichselbaum, Ralph R.

AU - Vokes, Everett E.

AU - Fetscher, Sebastian

AU - Lim Seiwert, Tanguy

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objectives Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown single agent activity against tumors with deficiencies in the DNA repair mechanism homologous recombination including, but not limited to those harboring BRCA mutations. We hypothesized that, in the context of homologous recombination deficiency (HRD), PARPi could have an effect in head and neck cancer (HNC). Materials and Methods We evaluated TCGA data for evidence of HRD using a copy number data signature established for breast cancer. The comparative potency of three PARPi was evaluated using cell viability assays in a panel of HNC cell lines and response was compared to BRCA-deficient breast cancer cell lines. The change in foci formation of γH2AX and RAD51 was assessed with immunofluorescent staining after exposure to a PARPi. Baseline gene expression was analyzed using microarray data. Results We found a subgroup in the TCGA HNC cohort harboring genomic aberrations consistent with HRD in breast cancer. Rucaparib activity was superior to olaparib and veliparib and showed single agent activity in a subset of HNC cell lines that was comparable to BRCA-deficient breast cancer cell lines. Rucaparib-sensitive and rucaparib-resistant groups showed significant differences in γH2AX and RAD51 foci formation after rucaparib exposure. Expression of genes involved in chromosome structure was strongly associated with rucaparib resistance. Conclusion We demonstrate that PARPi are effective in a subset of HNC cell lines and propose that HRD may be present in HNC in vivo suggesting that these compounds could play a role in the treatment of HNC.

AB - Objectives Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown single agent activity against tumors with deficiencies in the DNA repair mechanism homologous recombination including, but not limited to those harboring BRCA mutations. We hypothesized that, in the context of homologous recombination deficiency (HRD), PARPi could have an effect in head and neck cancer (HNC). Materials and Methods We evaluated TCGA data for evidence of HRD using a copy number data signature established for breast cancer. The comparative potency of three PARPi was evaluated using cell viability assays in a panel of HNC cell lines and response was compared to BRCA-deficient breast cancer cell lines. The change in foci formation of γH2AX and RAD51 was assessed with immunofluorescent staining after exposure to a PARPi. Baseline gene expression was analyzed using microarray data. Results We found a subgroup in the TCGA HNC cohort harboring genomic aberrations consistent with HRD in breast cancer. Rucaparib activity was superior to olaparib and veliparib and showed single agent activity in a subset of HNC cell lines that was comparable to BRCA-deficient breast cancer cell lines. Rucaparib-sensitive and rucaparib-resistant groups showed significant differences in γH2AX and RAD51 foci formation after rucaparib exposure. Expression of genes involved in chromosome structure was strongly associated with rucaparib resistance. Conclusion We demonstrate that PARPi are effective in a subset of HNC cell lines and propose that HRD may be present in HNC in vivo suggesting that these compounds could play a role in the treatment of HNC.

KW - DNA repair

KW - Head and neck cancer

KW - Homologous recombination

KW - Poly (ADP-ribose) polymerase

KW - Rucaparib

UR - http://www.scopus.com/inward/record.url?scp=84905924623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905924623&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2014.06.004

DO - 10.1016/j.oraloncology.2014.06.004

M3 - Article

C2 - 25017803

AN - SCOPUS:84905924623

VL - 50

SP - 825

EP - 831

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 9

ER -